AGP Executive Report
Last update: 8 hours agoCannabis Policy & Access: A new federal move reclassifies FDA-approved marijuana products and state medical cannabis from Schedule I to Schedule III, with lawmakers and industry watching how it could reshape rules and business in states like Pennsylvania. Medical Research: A scientific review reports cannabinoids show consistent anti-tumor effects in glioblastoma and breast cancer models, and may boost chemotherapy outcomes. Patient/Consumer Health: Inhaled insulin (Afrezza) is now FDA-approved for kids 6+ with Type 1 diabetes, adding a needle-free option for pediatric care. Public Health/Regulation: Vermont signed a landmark paraquat ban tied to Parkinson’s risk, with limited exemptions through 2030. Safety & Law: A retrial begins in the Davis stabbing spree case, where prosecutors are focusing on “cannabis-induced psychosis” as a factor. CBD/Wellness Culture: A “weed lowers testosterone” claim gets pushed back by a Swiss study finding cannabis users had higher androgen levels rather than lower testosterone.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About](https://ml.globenewswire.com/media/ae83c67f-909d-4427-80c0-3bc4826dfd96/medium/vapofil.png)
